MacroGenics to Participate in Upcoming Investor Conference
MacroGenics (Nasdaq: MGNX) has announced its participation in the 7th Annual Evercore HealthCONx conference in Coral Gables, FL. The company's President and CEO, Scott Koenig, M.D., Ph.D., will engage in a fireside chat on December 4, 2024, at 7:30am ET, alongside one-on-one meetings.
The presentation will be available via webcast in the Investor Relations section of MacroGenics' website, with an archived replay accessible for 30 days. MacroGenics specializes in developing and commercializing innovative monoclonal antibody-based therapeutics for cancer treatment.
MacroGenics (Nasdaq: MGNX) ha annunciato la sua partecipazione alla 7ª Annual Evercore HealthCONx conference a Coral Gables, FL. Il presidente e CEO dell'azienda, Scott Koenig, M.D., Ph.D., parteciperà a una chiacchierata informale il 4 dicembre 2024, alle 7:30 ET, oltre a incontri privati.
La presentazione sarà disponibile tramite webcast nella sezione Relazioni con gli Investitori del sito web di MacroGenics, con una registrazione archiviata accessibile per 30 giorni. MacroGenics si specializza nello sviluppo e nella commercializzazione di terapie innovative basate su anticorpi monoclonali per il trattamento del cancro.
MacroGenics (Nasdaq: MGNX) ha anunciado su participación en la 7ª Conferencia Anual Evercore HealthCONx en Coral Gables, FL. El presidente y CEO de la empresa, Scott Koenig, M.D., Ph.D., participará en una charla informal el 4 de diciembre de 2024, a las 7:30 a.m. ET, junto con reuniones uno a uno.
La presentación estará disponible a través de una transmisión en vivo en la sección de Relaciones con Inversores del sitio web de MacroGenics, con una repetición archivada accesible durante 30 días. MacroGenics se especializa en el desarrollo y la comercialización de terapias innovadoras basadas en anticuerpos monoclonales para el tratamiento del cáncer.
MacroGenics (Nasdaq: MGNX)는 플로리다주 코럴 게이블스에서 열리는 제7회 연례 Evercore HealthCONx 컨퍼런스에 참석할 것이라고 발표했습니다. 회사의 회장 겸 CEO인 Scott Koenig, M.D., Ph.D.는 2024년 12월 4일 오전 7시 30분 ET에 진행되는 화상 대화에 참여하며, 1:1 미팅도 예정되어 있습니다.
발표는 MacroGenics 웹사이트의 투자자 관계 섹션을 통해 웹캐스트로 제공되며, 30일 동안 아카이브된 재생이 가능합니다. MacroGenics는 암 치료를 위한 혁신적인 단클론 항체 기반 치료법의 개발 및 상용화에 전문화하고 있습니다.
MacroGenics (Nasdaq: MGNX) a annoncé sa participation à la 7e conférence annuelle Evercore HealthCONx à Coral Gables, FL. Le président et PDG de l'entreprise, Scott Koenig, M.D., Ph.D., participera à une discussion informelle le 4 décembre 2024 à 7h30 ET, ainsi qu'à des réunions en tête-à-tête.
La présentation sera disponible via webdiffusion dans la section Relations Investisseurs du site Web de MacroGenics, avec un replay archivé accessible pendant 30 jours. MacroGenics se spécialise dans le développement et la commercialisation de thérapies innovantes basées sur des anticorps monoclonaux pour le traitement du cancer.
MacroGenics (Nasdaq: MGNX) hat seine Teilnahme an der 7. jährlichen Evercore HealthCONx Konferenz in Coral Gables, FL, bekannt gegeben. Der Präsident und CEO des Unternehmens, Scott Koenig, M.D., Ph.D., wird am 4. Dezember 2024 um 7:30 Uhr ET an einem Gespräch teilnehmen, außerdem sind Einzelgespräche geplant.
Die Präsentation wird im Investor Relations-Bereich der Website von MacroGenics über einen Webcast verfügbar sein, und eine aufgezeichnete Wiederholung ist 30 Tage lang zugänglich. MacroGenics ist auf die Entwicklung und Kommerzialisierung innovativer monoklonaler Antikörpertherapien zur Krebsbehandlung spezialisiert.
- None.
- None.
ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month:
- 7th Annual Evercore HealthCONx (Coral Gables, FL). MacroGenics’ President and Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, December 4, 2024, at 7:30am ET. MacroGenics’ management will also participate in one-on-one meetings.
A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
FAQ
When is MacroGenics (MGNX) presenting at the Evercore HealthCONx conference 2024?
Where can I watch MacroGenics (MGNX) Evercore HealthCONx 2024 presentation?
How long will MacroGenics (MGNX) 2024 Evercore presentation replay be available?
What type of meetings will MacroGenics (MGNX) conduct at Evercore HealthCONx 2024?
